COVID-19 as good as cured

The research paper linked below points towards a cure for COVID-19. It is a paper not associated with Biotron (ASX:BIT), but their findings suggest that Biotron's compounds, "While not preventing future spreading of the virus, these inhibitors might reduce the mortality rate while effective vaccines are being developed."

A successful vaccine for SARS-CoV-2, like all great vaccines, will eventually stop or severely limit the spread of their target virus. Biotron is not presently working on making a vaccine, but rather, small molecule antivirals that exhibit a new mode of action quite different to other antivirals presently being used against diseases. Therefore, the concluding remarks quoted above from the paper linked below, remind us of the difference between antivirals and vaccines. However, we should keep in mind that Biotron's new mode of action can also be adapted to developing a vaccine, but in the mean-time, their technology will develop into a successful antiviral to 'cure' COVID-19, just as their compound BIT225 has been shown in tests so far to eradicate HIV from remaining infected human 'hidden' cells.

The theme of the linked research paper below, is that certain compounds used on SARS-COV-1 that inhibited the viroporin action of the essential E Protein, will also do the same on SARS-CoV-2, as both share the necessary genomic structure where the viroporin action occurs. This action leads to the acute lung damage in severe cases in both strains of SARS that often leads to death.

Biotron is presently testing their compounds on SARS-CoV-2, and initial results will be released in due course.

Biotron began its SARS work in 2003 at the outbreak of the disease, and was responsible for demonstrating for the first time that the E Protein was a viroporin, and that they could also close the Ion Channel that would result in preventing viral progeny. In doing so, they have created a new mode of action from other antiviral and vaccine methodology that mostly attempts to inhibit viral infusion at the S Protein. As the linked paper below shows, SARS-CoV-2 has distinct S Protein differences from its predecessor, which will result in a protracted outcome for other antivirals and vaccines to be altered.

https://www.biorxiv.org/content/10.1101/2020.02.17.952895v2.full.pdf